Boryung and HK inno.N have entered into an agreement for the joint marketing of their flagship drugs, Kanarb (pimasartan) and K-CAB (tegoprazan), starting January next year.

 Under this collaboration, Boryung will jointly market HK inno.N's K-CAB Tab and K-CAB ODT, while HK inno.N will jointly market Boryung's four Kanarb products: Kanarb, Dukaro, Dukarb, and Dukarb Plus.

Both Kanarb and K-CAB are blockbuster products, each achieving annual sales exceeding 100 billion won ($76.8 million) last year.

As a hypertension treatment, Kanarb has been continuously launching combination products and expanding treatment options to treat patients with various levels of hypertension as well as comorbidities.

K-CAB is a treatment for gastroesophageal reflux disease (GERD). Last year, HK inno.N also launched the K-CAB ODT, a formulation that dissolves in the mouth without water, improving patients’ convenience.

Boryung and HK inno.N will share their respective strengths in sales and marketing of circulatory and digestive therapies, respectively, to strengthen both products' market dominance and growth.

"We hope that the cooperation between the two companies and the two products will be established as a successful model for the industry and drug developers," said Daniel Chang, CEO of Boryung. "We expect to strengthen the status of K-drug representatives further and create new growth opportunities through our successful drug experience and clinical value-based sales and marketing capabilities."

"With both companies' experience in successfully bringing blockbuster drugs to market, we will maximize our synergies to consolidate our market leadership position," said Kwak Dal-won, CEO of HK inno.N. "We also plan to explore further partnership opportunities with Boryung to create a win-win situation."